{'fraction_non_alphanumeric': 0.028703703703703703, 'fraction_numerical': 0.004629629629629629, 'mean_word_length': 5.321637426900585, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Additional pharmacological aspects of orgotein, a metalloprotein with superoxide-dismutase activity.

Orgotein is a copper- and zinc-containing protein with superoxide-dismutase activity which can be isolated from bovine liver and erythrocytes. The effects of this drug on adjuvant -induced arthritis in rats, and particularly on the changes in erythrocytes sedimentation rates and plasma fibrinogen levels induced by this experimental infection, were studied. Orgotein was also assayed on nystatin-induced paw edema, passive cutaneous anaphylaxis and Arthus reaction, in rats. Finally, studies on platelet aggregation and the prostaglandin system were conducted. Given at doses of 2.5 and 5 mg/kg i.p. for 14 days to arthritic rats, orgotein normalized the serum changes, inhibited the foot swelling and improved the performance time on the rotating bar. The drug reduced, after a single dose, the nystatin-induced edema, whilst it showed no effects on the immunological inflammations, platelet aggregation and prostaglandin system. The probable mechanism of action is discussed.